In the NewsLilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability LitigationJune 9th, 2005. (Press Release) Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When finalized, the settlement will resolve the majority ... [More >>] FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly PatientsApril 11th, 2005. (Press Release) The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” These drugs are approved for the treatment of schizophrenia and mania, but ... [More >>] FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)April 7th, 2005. (Press Release) The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the FDA web site. ... [More >>] New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular ProfileApril 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>] Arthritis Drug Bextra Pulled; FDA Requests Revised Label on OTC NSAIDSApril 7th, 2005. What should I do if I am currently taking Bextra? You should speak with your doctor immediately to investigate options to discontinue Bextra and seek alternative treatments. Stevens-Johnson Syndrome In addition to cardiovascular problems, Bextra has been linked to a rare but sometimes ... [More >>] New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular ProfileApril 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>] Forbes Regional Hospital alerts 200 patients who received colonoscopies that they may be at risk for hepatitis, HIVMarch 31st, 2005. Did you receive a colonoscopy at Forbes Regional Hospital? Here is a checklist of important facts for patients who received the procedure at Forbes in Monroeville: Colonoscopes were inadequately cleaned between October 28, 2004 and February 26, 2005. There is a small risk of hepatitis and HIV as a result of the inadequate ... [More >>] FDA Statement on the Halting of a Clinical Trial of the Cox-2 Inhibitor CelebrexDecember 17th, 2004. (Press Release) The FDA today released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex (celecoxib): The Food and Drug Administration (FDA) learned last night from the National Cancer Institute (NCI) and Pfizer, Inc., that NCI has stopped drug administration in an ongoing clinical trial ... [More >>] Merck & Co., Inc. Response to an Editorial Posted on the New England Journal of Medicine Web SiteDecember 8th, 2004. In response to an editorial that appeared today on the New England Journal of Medicine website, Merck & Co., Inc. believes that it is important to emphasize that the company promptly and appropriately disclosed the results of the VIGOR (VIOXX Gastrointestinal Outcomes Research) study. Merck correctly communicated about the benefits ... [More >>] Vioxx drug recall; pain and arthritis drug shown to increase risks of stroke, heart attackSeptember 30th, 2004. Results of a recent study on Vioxx confirmed long-standing concerns that the drug increases the risk of stroke and heart attack, spurring maker Merck to voluntarily pull the drug worldwide (in some countries, the drug is marketed under the name "Ceoxx"). Vioxx is regularly prescribed for treatment of arthritis and acute ... [More >>] |
[site map] |
[ Goldberg, Persky & White, P.C. | 1030 Fifth Ave | Pittsburgh, PA 15219 | 800-471-3980 | Fax: 412-471-8308 | Email | Additional Offices ]
[ mesothelioma | nursing home abuse ]
Copyright 2003 Goldberg, Persky & White, P.C. The information provided by or linked to from this web site is intended to educate and inform victims of asbestos-related disease and other occupational injuries. The Goldberg, Persky & White, P.C. web site is intended for informational purposes only and is not to be construed as medical or legal advice. Visitors who are in need of legal or medical advice should consult with a professional licensed in their state of residence. The opinions expressed herein by persons or organizations other than Goldberg, Persky & White, P.C. are not necessarily endorsed by Goldberg, Persky & White, P.C. No attorney-client relationship is established by visiting our website or sending us Email. Copyright (c) 2003, Goldberg, Persky & White, P.C. All Rights Reserved.
Last Updated: February 05, 2008. 10:53:35 am
Pair
